- BioHarvest Sciences (CSE:BHSC) has appointed Eitan Popper as the company’s new Chairman of its Advisory Board
- Eitan co-founded and acted as President of MedReleaf, which was acquired in 2018 for approximately C$3.34 billion
- In his role as Chairman, he will assist the company’s management team in strategic matters and the development of key partnerships
- Eitan has also been granted a total of 10.8 million incentive stock options, exercisable at a price of 15 cents each over a 10-year period
- BioHarvest Sciences (BHSC) is currently up 3.33 per cent and is trading at 16 cents per share
BioHarvest Sciences (CSE:BHSC) has appointed Eitan Popper as the company’s new Chairman of its Advisory Board.
Eitan co-founded and acted as President of MedReleaf, which was acquired in 2018 for approximately C$3.34 billion in what is thought to be the largest exit in the cannabis industry to date.
In addition, he has more than 15 years of experience in international partnerships, various entrepreneurial ventures, commercial project management, engineering and investment exposure.
As Chairman of BioHarvest’s Advisory Board, Eitan will assist the company’s senior management in key strategic matters, including the development of pivotal relationships to facilitate BioHarvest’s wider strategic plan.
Zaki Rakib, Chairman of BioHarvest’s Board of Directors, said Eitan’s valuable experience will help the company to implement its biofarming technology within the cannabis sector.
“Co-operating with existing successful players in the industry will accelerate the adoption of the Company’s technology, which is set to change cannabis production as we know it.
“In his role as Chairman of the Board of Advisors, Mr Popper will also be identifying and incorporating additional advisors who will further support the company’s growth,” he said.
Eitan holds a degree in civil engineering from the UIA in Mexico, an MBA from the Recanati School of Business at Tel Aviv University and a Master’s in Environmental Fluid Mechanics from Stanford University.
In connection with his appointment, BioHarvest has granted Eitan a total of 10.8 million incentive stock options, exercisable at a price of 15 cents each for a period of ten years and vesting on a quarterly basis over a two-year period.
Commenting on his appointment, Eitan said he is looking forward to working with the company as it further scales its unique plant cell technology platform.
“I was fortunate to meet the BHSC team over a year ago, and since then have visited the company’s GMP and ISO certified facilities multiple times.
“I was very impressed when I learned about the company’s proprietary technology, as it allows to produce any herbal API and full spectrum plant-based products, at industrial scale, under GMP conditions, and at a fraction of the price when compared to conventional farming and extraction,” he said.
BioHarvest Sciences (BHSC) is currently up 3.33 per cent to $0.16 per share at 2:34pm EDT.
